Five-Year Peptide Supply Deals: Lessons from Amylyx and Bachem

Pillar 1: Quantify Your Demand Uncertainty Before You Commit

The most common error in long-term peptide supply agreements is binding volume commitments to a demand forecast that has not been stress-tested against the program’s actual clinical and regulatory uncertainty.

The Amylyx-Bachem agreement defers minimum purchase obligations to 2028 — at least two years after signing. That gap is not generosity; it is a recognition that avexitide’s commercial volumes depend on FDA approval timing, label scope, and payer access decisions that remain unresolved at contract execution. The structure separates capacity reservation (which can be done early) from volume commitment (which begins only once the demand envelope becomes more tractable).

Before accepting a minimum annual quantity (MAQ) clause, run three scenarios across your forecast model:

• Base case: approval in expected window, label matches target indication

• Delay case: twelve-to-eighteen month approval lag, no impact on indication scope

• Downside case: narrow label approval, restricted market access, or pipeline deprioritization

If the MAQ exceeds your downside-case volume by more than 20–25%, you are effectively buying insurance for a capacity tier you may never need — and paying take-or-pay penalties when you fail to absorb it. Negotiate step-down provisions that allow volume floor reductions in response to documented regulatory or commercial triggers. The standard language from SEC-filed API supply agreements allows sponsors to invoke force majeure or material adverse change clauses, but these remedies are difficult to invoke and invariably contested; a pre-negotiated step-down mechanism is far more operationally useful.

⚠️ Failure Mode: Signing a flat MAQ tied to base-case launch assumptions, then absorbing take-or-pay fees of 20–40% of unordered volume when a delayed approval or restricted label compresses commercial uptake below forecast.

Pillar 2: Understand What You Are Actually Paying for in Reservation Economics

The Polypeptide Group term sheet included a $30 million upfront capacity reservation fee — a number that is large enough in absolute terms to carry significant board-level scrutiny, but which reflects an increasingly normal cost structure for GMP peptide manufacturing capacity at scale.

Reservation economics in peptide CDMO agreements now typically include two distinct financial instruments that are often conflated:

1. Capacity reservation fee (CRF): a fixed payment, often non-refundable or only partially creditable against future purchase invoices, that secures named manufacturing slots for a defined peptide, purity specification, batch size, and release standard. The fee compensates the CDMO for holding capacity against a firm commitment rather than filling it opportunistically with other clients’ campaigns.

2. Maintenance fees: recurring payments covering quality oversight, regulatory file maintenance, method retention, and periodic campaign preparation activities during periods of low or no active manufacturing — what the Amylyx-Bachem disclosure refers to as “maintenance fees and expenses.”

The distinction matters for financial modeling. A CRF is a sunk capital cost tied to option value; maintenance fees are recurring operational costs that continue even in years when no manufacturing runs occur. Both must appear in the net present cost calculation across the agreement term.

Before signing, extract answers to four questions from the draft agreement:

1. Is the CRF fully creditable, partially creditable, or forfeited on cancellation?

2. Under what conditions does the CRF convert to an enforceable obligation (i.e., when does the option become a liability)?

3. What triggers a maintenance fee invoice, and what is the audit right attached to it?

4. If the primary site cannot fulfill a reserved slot, does the CDMO have an obligation to provide an equivalent slot at an alternate qualified facility — and within what timeline?

The third question is frequently underdefined in first-draft agreements. Tier-1 CDMOs operating at scale commonly include language allowing unilateral rescheduling of reserved slots within a defined window, sometimes as short as thirty days, with no monetary remedy to the sponsor. Negotiate explicit remedies — accelerated delivery rights, priority rebooking within a defined period, or fee credits — before the agreement is executed.

Sintesis Peptida Per current CDMO pricing analysis, Tier-1 CDMOs now routinely require 10–20% advance reservation deposits for research-scale agreements and 40–50% upfront non-refundable commitments for commercial-scale capacity. Understanding where your deal sits in that range — and why — is a foundational negotiation input.

Pillar 3: Map Technical-Transfer Readiness Before You Lock In a Partner

A supply agreement binds you commercially to a specific CDMO partner. Technical transfer complexity determines how easily you can exit that binding if circumstances change — and how much switching costs will constrain your negotiating leverage on renewals.

Peptide Contract Manufacturing Pricing Trends Q2 2026 places technology transfer costs for complex peptide APIs at $300,000–$800,000 or more, depending on process complexity, analytical method portfolio size, and GMP documentation burden. That range creates significant lock-in for programs with difficult sequences, multi-step modifications, or extensive stability-indicating method sets. The higher your transfer cost, the more leverage your CDMO has at renewal — and the more important it is to build transfer readiness into the original agreement.

Technical transfer readiness is best evaluated across four dimensions before signing:

An agreement that does not address method transfer protocol ownership, DMF filing rights, or post-agreement analytical record retention is one that hands the CDMO de facto veto power over any future transition. Negotiate:

• Sponsor access to batch records and analytical data within a defined period of request

• A right to conduct technical transfer to a qualified secondary or Peptida sintetik tertiary site during the agreement term (not only at termination)

• Specific timelines and cost-sharing provisions for any required re-validation at a new site

The EMA Guideline on the Development and Manufacture of Synthetic Peptides provides the regulatory baseline for what analytical controls must be in place for GMP-grade synthetic peptide APIs. Your transfer readiness assessment should verify that the CDMO’s current control strategy satisfies this standard — not merely that they assert it does.

Pro Tip: Request a “transfer readiness simulation” as part of final due diligence: ask the CDMO to provide the batch record index, method list, and DMF chapter inventory they would need to transfer to demonstrate readiness. Gaps in that inventory are negotiation leverage before signing — they become contractual disputes after.

Pillar 4: Build Contingency Sourcing Into the Agreement Architecture, Not as an Afterthought

The Amylyx-Bachem agreement is explicitly non-exclusive: Bachem is one of two simultaneously engaged CDMOs, with Polypeptide Group holding a parallel supply commitment. This structural choice reflects a clear risk management posture — single-source dependence for a commercial peptide API is no longer considered acceptable practice by biopharma legal and supply chain teams who have experienced the post-2020 supply disruption environment.

Dual-sourcing for peptide APIs is not simply about having a backup vendor on file. A backup vendor that has not completed analytical comparability, process qualification, or regulatory file alignment is operationally unavailable when you need it. The operational standard, validated by building a resilient peptide supply chain, is a staggered second-source protocol:

Phase 1 (Months 1–3): Desk audit and analytical method transfer to secondary vendor. CoA comparability study using split-lot samples. No active manufacturing commitment.

Phase 2 (Months 4–9): Pilot comparability batches at secondary site. Analytical equivalence assessment for identity (ESI-MS or MALDI-TOF), kemurnian (RP-HPLC), and impurity profiles. Regulatory file alignment.

Phase 3 (Ongoing): Standing bridge allocation of 10–20% of routine purchase volume to secondary vendor. This maintains the secondary site’s production continuity and team familiarity with the process without incurring full commercial duplication costs.

The contingency sourcing provision in the primary supply agreement should explicitly address:

• The sponsor’s right to qualify and activate a secondary source during the agreement term, without triggering a breach-of-exclusivity claim (particularly if the primary agreement contains any preferred-supplier language)

• Defined escalation triggers that convert the secondary vendor from standby to primary allocation — delivery SLA failures, batch release failures above a defined frequency threshold, regulatory action, or material financial distress

• Supplier switching timeline commitments: what is the maximum number of days from trigger activation to first commercial batch delivery from the secondary source?

Per the dual-sourcing strategy guidance for biopharma, a 70/30 utawa 60/40 commercial split across primary and secondary CDMOs is an operational benchmark that maintains secondary-source readiness without imposing equivalent cost to full parallel manufacturing.

⚠️ Failure Mode: Qualifying a secondary CDMO on paper but not in practice — no pilot batches completed, no analytical comparability data on file, no regulatory filing amendments to add the alternate site. When the primary site has a capacity shortfall or quality excursion, the backup cannot legally supply commercial-grade material.

Pillar 5: Define Release Testing Responsibilities with Contractual Precision

Release testing responsibility is the most commonly under-specified element in peptide API supply agreements, and the most consequential when a batch fails or a specification dispute arises.

The Amylyx-Bachem agreement allocates testing and supply responsibilities to Bachem as the manufacturer, with Amylyx retaining product specification authority and final lot disposition rights as the sponsor/applicant. This is the standard architecture under ICH Q7 and standard industry quality agreements — but the details within that architecture matter enormously.

For a GMP synthetic peptide API, minimum release specifications require orthogonal analytical coverage per regulatory guidance. According to PolypPeptide’s CMC quality control white paper, lot release specifications must be sufficient to establish identity, kemurnian, strength, and where applicable, safety (endotoksin, sterility) of the peptide API. A practical minimum release panel includes:

Beyond the panel itself, the quality agreement attached to the supply agreement must clearly assign responsibility for:

• Testing authority: who performs each test, and at which site (CDMO QC, sponsor QC, or independent third-party laboratory)?

• OOS investigation ownership: when a result falls outside specification, who initiates the investigation, what is the timeline, and what authority does the CDMO have to release a lot pending investigation resolution?

• Lot disposition authority: the CDMO typically performs provisional internal QC disposition; the sponsor retains final release authority for GMP lots intended for clinical or commercial use

• CoA format and data retention: the CoA must include batch number, all test results with raw data references (chromatograms, spectra), analyst ID, and release date. Data retention obligations and sponsor access rights should be defined contractually, not left to the CDMO’s internal SOPs

This distribution of testing and disposition authority is the contractual backbone of your lot-level risk management. When a batch fails, ambiguity about who owns the investigation or the release decision translates directly to timeline risk and regulatory exposure.

Applying the Framework: A Pre-Signature Checklist

The five pillars above convert to a structured pre-signature review that can be completed across a standard legal and technical due diligence cycle. For each pillar, the minimum acceptance condition is:

Any cell left blank or answered with “to be defined” before signing is a gap that will need to be resolved — under worse conditions — after execution.

Working With Your CDMO Partner on Agreement Terms

The framework above is an evaluation and negotiation tool, not a prescriptive contract template. Real supply agreement negotiations involve counterpart constraints, market capacity realities, and relationship context that generic checklists cannot capture. The most productive outcome of applying this framework is a structured conversation with your CDMO counterpart about which provisions are standard, which are negotiable, and which require creative structural solutions.

For biopharma development teams building peptide programs from the milligram-to-kilogram scale, having a CDMO partner with explicit expertise in technical transfer, analytical method development, and quality agreement architecture reduces the friction in each of these five areas. MOL Changes supports peptide synthesis programs across the full development continuum — from complex custom sequences requiring 300+ functional group modifications to GMP-compatible production in Class 100 cleanroom environments with full HPLC, MS, and endotoxin QC — and can provide a technical feasibility assessment to help teams understand their specific agreement risk profile before negotiations begin.

The Amylyx-Bachem agreement, read at the level of its contractual mechanics rather than its headline announcement, is a useful reference point. Every team entering a multi-year peptide supply commitment should be able to account for each of the five pillars described above — not because the deal terms are identical to Amylyx’s, but because the categories of risk are.

Reviewed by the MOL Changes Peptide Science Team. MOL Changes is a commercial-stage peptide synthesis and CDMO services provider; the framework in this article reflects industry-standard practice and publicly available regulatory guidance, not proprietary claims.